Diclofenac Prolongs Repolarization in Ventricular Muscle with Impaired Repolarization Reserve

Attila Kristóf1, Zoltán Husti1, István Koncz1, Zsófia Kohajda2, Tamás Szél1, Viktor Juhász1, Péter Biliczki1, Norbert Jost2, István Baczkó1, Julius Gy Papp1,2, András Varró1,2*, László Virág1,2

1Department of Pharmacology and Pharmacotherapy, University of Szeged, Szeged, Hungary, 2Division of Cardiovascular Pharmacology, Hungarian Academy of Sciences, Szeged, Hungary

Abstract

Background: The aim of the present work was to characterize the electrophysiological effects of the non-steroidal anti-inflammatory drug diclofenac and to study the possible proarrhythmic potency of the drug in ventricular muscle.

Methods: Ion currents were recorded using voltage clamp technique in canine single ventricular cells and action potentials were obtained from canine ventricular preparations using microelectrodes. The proarrhythmic potency of the drug was investigated in an anaesthetized rabbit proarrhythmia model.

Results: Action potentials were slightly lengthened in ventricular muscle but were shortened in Purkinje fibers by diclofenac (20 μM). The maximum upstroke velocity was decreased in both preparations. Larger repolarization prolongation was observed when repolarization reserve was impaired by previous BaCl2 application. Diclofenac (3 mg/kg) did not prolong while doxefilide (25 μg/kg) significantly lengthened the QTc interval in anesthetized rabbits. The addition of diclofenac following reduction of repolarization reserve by doxefilide further prolonged QTc. Diclofenac alone did not induce Torsades de Pointes ventricular tachycardia (TdP) while TdP incidence following doxefilide was 20%. However, the combination of diclofenac and doxefilide significantly increased TdP incidence (62%). In single ventricular cells diclofenac (30 μM) decreased the amplitude of rapid (Ik1) and slow (Ii) delayed rectifier currents thereby attenuating repolarization reserve. L-type calcium current (ICa) was slightly diminished, but the transient outward (Ito) and inward rectifier (IK1) potassium currents were not influenced.

Conclusions: Diclofenac at therapeutic concentrations and even at high dose does not prolong repolarization markedly and does not increase the risk of arrhythmia in normal heart. However, high dose diclofenac treatment may lengthen repolarization and enhance proarrhythmic risk in hearts with reduced repolarization reserve.

Introduction

Drug induced prolongation of cardiac repolarization that manifests on the surface ECG as QT interval lengthening is considered to represent enhanced risk for proarrhythmia and sudden cardiac death. Recently, several non-cardiac drugs were withdrawn from the market and the development of numerous compounds were halted at the preclinical stage due to their proarrhythmic effects, indicating that safety pharmacological concerns and monitoring in this respect are now more rigorous than they were in the past. Therefore, it can be speculated that several drugs approved earlier and used widely today would not reach clinical phase of development due to failing at current, more rigorous safety pharmacology tests. However, the vast majority of drugs developed earlier and successfully applied today do not enhance proarrhythmic risk in the normal heart. On the other hand, there are certain situations when cardiac repolarization reserve [1–3] is attenuated due to ion channel protein encoding gene mutations, diseases or even lifestyle when otherwise minor subthreshold drug effects on cardiac repolarization may enhance repolarization instability with subsequently elevated proarrhythmic risk.

As a possible example for such situations, a number of sudden deaths of young athletes were reported in the past several years. The majority of these events were sudden cardiac deaths (SCD) attributed to ventricular fibrillation. Fortunately, the incidence of SCD of young athletes is quite low (around 1–2/100 000), however, it is still 2–4 times more frequent than in the age-matched population not participating in competitive sport [4]. There are a number of factors that can play a significant role in the
development of SCD in young athletes [5]. Cardiac hypertrophy is considered as one of the most important risk factors that has been associated with a characteristic electrical remodeling [6] that involves the downregulation of cardiac potassium channels, including $I_{Ks}$, a repolarizing current that has a uniquely important role in cardiac ventricular repolarization reserve [7,8]. Further important factors that influence arrhythmia disposition include various other cardiovascular diseases, hypokalemia, doping and seemingly harmless medications.

These medications may include non-steroid anti-inflammatory (NSAID) drugs often taken by athletes to alleviate pain related to sports injuries. Diclofenac is such a drug that is widely used for this purpose. Diclofenac intake has been associated with sudden death in four professional soccer players in a television show, however, scientifically this claim was not very well documented [9]. In this report, the pathologist Jørgen Lange Thomsen attributed these fatalities to coronary constriction as a possible consequence of cyclooxygenase enzyme (COX) inhibition [9]. However, one can speculate that different mechanisms may also be involved including direct cardiac electrophysiological effects on potassium channels with consequent changes in ventricular repolarization.

Diclofenac is a nonselective NSAID drug, which blocks COX-1 and COX-2 enzymes and is widely used as an anti-inflammatory and analgesic drug. There is growing concern regarding increased cardiovascular risks of NSAIDs application [10–12], however, very little is known about the cardiac electrophysiological effect of these drugs. Therefore, detailed characterization of the possible effects of diclofenac, one of the most frequently applied NSAIDs, on ventricular repolarization and transmembrane ionic currents and further consideration of the possible proarrhythmic potency of the drug seems reasonable since it can not be ruled out that its possible proarrhythmic potency might contribute to the higher incidence of SCD in young athletes. Such studies are justified by the fact that diclofenac is very often used in large doses for the treatment of sports injuries [13].

In the present study, the cellular electrophysiological effects of diclofenac were characterized including its effects on the main transmembrane ionic currents in single ventricular myocytes as well as on the action potential characteristics in canine isolated ventricular muscle and Purkinje fibers. The possible proarrhythmia potency of the drug was also investigated in an anaesthetized rabbit proarrhythmia model.

Methods

Ethics Statement

All experiments were carried out in compliance with the Guide for the Care and Use of Laboratory Animals (USA NIH publication NO 85–23, revised 1996) and conformed to the Directive 2010/63/EU of the European Parliament. The protocols have been approved by the Ethical Committee for the Protection of Animals in Research of the University of Szeged, Szeged, Hungary (approval number: I-74-5-2012) and by the Department of Animal Health and Food Control of the Ministry of Agriculture and Rural Development (authority approval number XIII/1211/2012).

Conventional Microelectrode Technique

Adult mongrel dogs (8–14 kg) of either sex were used. Following sedation (xylazine, 1 mg/kg, i.v.) and anaesthesia (thiopental, 30 mg/kg i.v.), the heart was rapidly removed through right lateral thoracotomy. The hearts were immediately rinsed in oxygenated modified Locke’s solution containing (in mM): NaCl 120, KCl 4, CaCl$_2$ 1.0, MgCl$_2$ 1, NaHCO$_3$ 22, and glucose 11. The pH of this solution was set between 7.35 and 7.4 when saturated with the mixture of 95% $O_2$ and 5% $CO_2$ at 37°C. Isolated muscle preparations obtained from the right ventricle and Purkinje fibers were individually mounted in a tissue chamber with a volume of 50 ml. These preparations were stimulated through a pair of platinum electrodes in contact with the preparation using rectangular current pulses of 2 ms duration. These stimuli were delivered at a constant cycle length of 1 s (500 ms for Purkinje fibers) for at least 60 min allowing the preparation to equilibrate before the measurements were initiated. Transmembrane potentials were recorded using conventional glass microelectrodes, filled with 3 M KCl and having tip resistances of 5–20 MΩ, connected to the input of a high impedance electrometer (Experimeträa, type 309, Budapest, Hungary) which was coupled to a dual beam oscilloscope. The maximum diastolic potential, action potential amplitude, maximum upstroke velocity ($V_{up}$) and action potential duration measured at 50% and 90% of repolarization (APD$_{50}$ and APD$_{90}$, respectively) were off-line determined using a home-made software running on an IBM compatible computer equipped with an ADA 3300 analogue-to-digital data acquisition board (Real Time Devices Inc., State Collage, PA, USA) having a maximum sampling frequency of 40 KHz. The following types of stimulation were applied in the course of the experiments: stimulation with a constant cycle length of 1000 ms (ventricular muscles); stimulation with a constant cycle length of 500 ms (Purkinje fibres); stimulation with constant different cycle lengths ranging from 300 to 5000 ms (or to 2000 ms in the case of Purkinje fibers to prevent spontaneous diastolic depolarization at cycle lengths longer than 2000 ms). Attempts were made to maintain the same impalement throughout each experiment. In case an impalement became dislodged, adjustment was attempted, and if the action potential characteristics of the re-established impalement deviated by less than 5% from the previous measurement, the experiment continued.

Whole Cell Patch-clamp

Ventricular myocytes were enzymatically dissociated from dog hearts using the segment perfusion technique as described earlier in detail [7]. One drop of cell suspension was placed in a transparent recording chamber mounted on the stage of an inverted microscope. The myocytes were allowed to settle and adhere to the bottom for at least 5 minutes before superfusion was initiated. Only rod shaped cells with clear cross-striations were used. Cells were superfused with HEPES-buffered Tyrode solution containing (in mM): NaCl 144, NaH$_2$PO$_4$ 0.4, KCl 4.0, CaCl$_2$ 1.8, MgSO$_4$ 0.53, glucose 5.5, and HEPES 5.0. The pH was set to 7.4 and the temperature to 37°C.

Patch-clamp micropipettes were fabricated from borosilicate glass capillaries (Harvard Apparatus Ltd, Edenbridge, Kent, UK) using a micropipette puller (Flaming/Brown, type P-97, Sutter Co, Novato, CA, USA). These electrodes had resistances between 1.5 and 2.5 MΩ when filled with pipette solution containing (in mM): K-aspartate 100, KCl 40, ATP 5, MgCl$_2$ 5, EGTA 4, CaCl$_2$ 1.5 and HEPES 10. The pH of this solution was adjusted to 7.2 by KOH. When measuring potassium currents, 1 μM nisoldipine (gift from Bayer AG, Leverkusen, Germany) was added to the external solution to eliminate L-type Ca$^{2+}$ current ($I_{CaL}$). The slow component of the delayed rectifier potassium current ($I_{Kr}$) was inhibited by using the selective $I_{Kr}$ blocker HMR 1556 (0.5 μM). In some experiments, the rapid component of the delayed rectifier potassium current ($I_{Kr}$) was blocked by 0.1 μM dofetilide. The $I_{Kr}$ current was recorded in HEPES buffered Tyrode’s solution containing 3 mM 4-aminopyridine in order to block the transient outward potassium current ($I_{to}$) and a special $K^+$ free pipette solution was used (composition in mM: CsOH 100, CaCl$_2$ 0.5).
20, TEACl 20, MgATP 5, HEPES 10, CaCl₂ 1.5, GTP 0.1, the pH was adjusted to 7.2 with aspartic acid). Membrane currents were recorded with Axopatch 200B patch-clamp amplifiers (Molecular Devices Inc., Sunnyvale, CA, USA) using the whole-cell configuration of the patch-clamp technique. After establishing a high resistance (1–10 GΩ) seal by gentle suction, the cell membrane beneath the tip of the electrode was disrupted by suction or application of short electrical pulses. The series resistance typically ranged from 4 to 8 MΩ before compensation (50%–80%). Experiments were discarded, when the series resistance was high or substantially increased during the measurement. Membrane currents were digitized after low-pass filtering at 1 kHz using analog-to-digital converters (Digidata 1322A and 1440A, Molecular Devices Inc., Sunnyvale, CA, USA) under software control (pClamp 8 and 10, Molecular Devices Inc., Sunnyvale, CA, USA). The same software was used for off-line analysis.

ECG Measurements in Anaesthetized Rabbits

Male New Zealand white rabbits (2–3 kg) were used for the experiments. The animals were anaesthetized with thiopental (50 mg/kg, i.v.) given into the marginal vein of the right ear. A plastic catheter filled with isotonic saline containing 500 IU/mL heparin was inserted into the left carotid artery for the measurement of arterial blood pressure. The right jugular vein was cannulated for i.v. drug administration. The animals were allowed to stabilize for 20 min before baseline measurements were taken.

The blood pressure and the electrocardiogram (limb leads I, II and III) were continuously recorded (at 2 kHz), digitized and stored on a computer for off-line analysis using National Instruments data acquisition hardware (National Instruments, Austin, TX, USA) and SPEL Advanced Haemosys software (v3.2, Experimetria Ltd., Budapest, Hungary). The RR and QT intervals were measured as the average of 10 beats. During the measurement of the QT interval in anaesthetized rabbits, the guidelines described by Farkas et al. [14] were followed. The frequency corrected QT interval (QTc) was calculated by a formula specifically worked out for anaesthetized rabbits by Batey and Coker [15] for more accurate monitoring of heart rate dependent changes in the QT interval, as follows: QTc = QT – (0.704 * (RR-250)).

All intravenous infusions were administered using a programmable infusion pump (Terufusion TE-3, Terumo Europe, Leuven, Belgium). The first group of rabbits received 3 mg/kg diclofenac (Sigma-Aldrich, Hungary) in a 10 min infusion in a volume of

Figure 1. Effect of diclofenac on action potentials in canine right ventricular muscle preparations and in Purkinje fibers. Representative superimposed records (top) demonstrating the effect of 20 μM diclofenac on action potential configuration at 1 s stimulation cycle length (A, right ventricular muscle; B, Purkinje fiber). Cycle length dependent changes in action potential duration (APD₉₀) measured under control conditions and in the presence of 20 μM diclofenac (bottom) in canine right ventricular muscle preparations (A) and in Purkinje fibers (B). Data are expressed as mean ± SEM, n = number of measurements/number of animals.

doi:10.1371/journal.pone.0053255.g001
2 ml/kg followed by 25 μg/kg dofetilide (Gedeon Richter Ltd., Budapest, Hungary) with 15 min equilibrium between infusions. The second group was administered the same dose of compounds in the reverse order.

Statistics
The incidence of TdP was compared using the $\chi^2$-test, with Yates’ correction. All other data are expressed as arithmetic mean ± S.E.M. values. Statistical differences were evaluated with one-way analysis of variance (ANOVA). Differences were considered significant when $p<0.05$.

Results
Effects of Diclofenac on Action Potential
The effects of diclofenac on action potential configuration were studied in canine right ventricular muscle preparations and Purkinje fibers. The result obtained is shown in Figure 1A top panel. Small, but statistically significant action potential lengthening was induced by diclofenac (20 μM) at a basic stimulation frequency of 1 Hz in right ventricular muscle preparations (APD$_{90}$ from 222.3±4.1 ms to 232.2±3.4 ms; APD$_{50}$ from 185.3±5.7 ms to 198.3±4.1 ms; n = 13/13 animals, p<0.05). The maximum upstroke velocity was also decreased by the drug (control: 168.8±15.7 V/s, 20 μM diclofenac: 136.6±13.2 V/s; n = 13/13 animals, p<0.05) at cycle length of 1000 ms. To study the rate-dependent effect of the drug on APD$_{90}$, the preparations were stimulated at cycle lengths ranging from 300 to 5000 ms. Under these circumstances diclofenac produced a slight rate-independent APD prolongation (Figure 1A bottom panel). In canine Purkinje fibers, however, the drug significantly shortened the action potential duration (APD$_{90}$ from 248.1±10.9 ms to 250.8±9.7 ms; APD$_{50}$ from 177.8±12.8 ms to 152.0±12.5 ms; n = 6 preparations/6 animals, p<0.05) and decreased $V_{\text{max}}$ (from 673.9±8.5 V/s, to 562.4±27.0 V/s, n = 6 preparations/6 animals, p<0.05) at basic cycle length of 500 ms indicating a sodium channel blocking property of the drug [16]. The shortening of APD$_{90}$ was rate-independent (Figure 1B).

The influence of diclofenac on action potential repolarization in preparations with impaired repolarization reserve was also investigated. Repolarization reserve was greatly attenuated by the application of 30 μM BaCl$_2$, which partially blocks the inward rectifier potassium current (I$_{\text{K}_1}$) in dog right ventricle [17]. BaCl$_2$ lengthened APD in a reverse frequency dependent manner (Figure 2). In the presence of BaCl$_2$, 20 μM diclofenac was added to these preparations. The drug induced a marked further lengthening relative to the APD$_{90}$ values measured after the administration of BaCl$_2$ (APD$_{90}$ to diclofenac: 309.8±15.2 ms vs. BaCl$_2$: 283.5±15.3 ms; APD$_{50}$: 241.0±10.5 ms vs. 225.2±12.6 ms; n = 11 preparations/9 animals, p<0.05, at cycle length of 1000 ms), i.e. APD lengthening effect of diclofenac was significantly augmented in preparations where the “repolarization reserve” was attenuated by previous application of BaCl$_2$ (Figure 2). Under these circumstances the drug produced reverse rate-dependent APD prolongation (Figure 2B).

Rationale for the Use of Anaesthetized Rabbit Proarrhythmia Model
Since the introduction of the Carlsson’s rabbit proarrhythmia model [18], the anaesthetized rabbit has been extensively used in different in vivo proarrhythmia studies for the assessment of arrhythmia risk associated with a compound of interest (for a comprehensive review see [19]). Therefore, two sets of experiments were also carried out in anaesthetized rabbits investigating the effects of diclofenac alone and in combination with the I$_{\text{K}_1}$ blocker dofetilide (impairing repolarization reserve) on cardiac repolarization and the development of Torsades de Pointes ventricular tachycardia (TdP).
Diclofenac (3 mg/kg) did not increase the RR interval either when given first (230.2±6.98 vs. 229.4±6.02 ms in control, p>0.05) or when it was administered following dofetilide infusion (252.1±7.73 ms vs 250.4±5.97 ms, p>0.05). Dofetilide, on the other hand, increased the RR interval both when given first (250.4±5.97 ms vs. 242.9±4.20 ms, p<0.05) and when it was administered following diclofenac infusion (240.3±8.21 ms vs. 230.2±6.80 ms, p<0.01). As shown on Figure 3A, diclofenac (3 mg/kg) did not change the QTc interval, while as expected, dofetilide (25 μg/kg) significantly lengthened QTc in anaesthetized rabbits. The combination of diclofenac and dofetilide significantly prolonged QTc, irrespective of the order of administration (Fig. 3A). Figure 3B and C illustrate the incidence of Torsades de Pointes arrhythmias in anaesthetized rabbits following the administration of diclofenac, dofetilide and their combination. Importantly, diclofenac alone did not induce TdP in any of the 13 animals examined, while TdP incidence following dofetilide was 20%, which corresponds well with our previous observations in this model [20]. However, the animals were not devoid of arrhythmias after diclofenac administration: 8 out of 13 exhibited frequent ventricular extra beats, and 7 out of 13 developed bigeminy. On the other hand, the combination of diclofenac and dofetilide led to a significant increase in the incidence of TdP and the increase was highest (62%) when diclofenac was administered first, indicating that further potassium channel inhibition following prior impairment of repolarization reserve can lead to increased frequency of serious arrhythmia development (Fig. 3B).

**Effects of Diclofenac on Transmembrane Ionic Currents**

The effects of the drug on the 4-aminopyridine sensitive Ito, as well as on I_{Ks}, I_{Kr}, I_{ks}, and I_{Ca} were investigated in canine ventricular myocytes. As shown in Figure 4A and 4B, diclofenac (even at 50 μM concentration) did not influence I_{to} or I_{Kr} currents. I_{to} current was activated by 300 ms long depolarizing voltage pulses from the holding potential of −90 mV to test potentials ranging from −20 to +60 mV with a pulse frequency of 0.33 Hz. The amplitude of I_{to} was measured as the difference between the peak and the sustained current at the end of the voltage pulse. I_{K1} current was measured as the steady-state current level at the end of the 300 ms long voltage pulse in the voltage range of −100 to 0 mV with a pulse frequency of 0.33 Hz. The holding potential was −90 mV.

I_{K1} and I_{KS} were measured using 1000 μM (I_{K1}) or 5000 μM-long (I_{KS}) test pulses between −30 mV and +50 mV (I_{K1}) or −20 to +50 mV (I_{KS}). The holding potential was −80 mV and during I_{K1} measurements 500 ms long prepulse to −40 mV was applied in order to ensure the baseline region. The pulse frequency was 0.05 Hz (I_{K1}) or 0.1 Hz (I_{KS}). The decaying tail current at −40 mV after the test pulse was assessed as I_{K1} or I_{KS}. The amplitudes of the I_{K1} and I_{KS} tail currents were determined as the difference between the peak tail current and the steady-state current level at −40 mV (baseline). When measuring I_{K1}, HMR-1556 (500 nM) was used to completely block I_{K1}, while dofetilide (0.1 μM) was added to the bath solution when studying I_{KS}. The top panels of Figure 5A and 5B show original I_{K1} and I_{KS} current traces in the absence and presence of 30 μM diclofenac, and indicate a significant blockade of I_{K1} (at 20 mV test potential; from 57.7±5.5 pA to 36.2±2.3 pA, n=5 cells/4 animals, p<0.05) and of I_{KS} (at 20 mV test potential; from 229.6±15.0 pA to 126.5±10.5 pA, n=6 cells/4 animals, p<0.05) by diclofenac. The corresponding bottom panels show the current-voltage relationships of I_{K1} (Fig. 5A) and I_{KS} (Fig. 5B) before and following superfusion with 30 μM diclofenac. I_{Ca} was recorded in the presence 3 mM 4-aminopyridine in order to block I_{to}. The current was evoked by 400 ms-long
depolarizing test pulses to voltages between −35 to +55 mV. The holding potential was −80 mV and a 75 ms-long prepulse to −40 mV was applied in order to inactivate the sodium current. The pulse frequency was 0.2 Hz. The amplitude of I_{Ca} was defined as the difference between the peak inward current at the beginning and the current at the end of the pulse. Diclofenac (30 μM) slightly but statistically significantly decreased the amplitude of the current (at 0 mV test potential; from 730.5±79.8 pA to 623.2±82.4 pA, n = 6 cells/4 animals, p<0.05) as indicated on Figure 6.

Discussion

The main results of the present study show that in the normal heart, diclofenac does not exert marked cardiac electrophysiological effects and does not enhance proarrhythmic risk, however, in hearts where repolarization reserve is attenuated, its moderate inhibition of I_{Kr} and I_{Ks} may lead to prolongation of ventricular repolarization and may also enhance proarrhythmic risk.

Our results indicate that diclofenac influences transmembrane ionic currents in canine ventricular myocytes, inhibiting I_{Kr}, I_{Ks}, and I_{Ca} currents but leaving I_{Na} and I_{K1} unchanged. Only a slight action potential lengthening was induced in ventricular muscle preparations and in Purkinje fibers the drug shortened the action potential duration. The maximum upstroke velocity was decreased in both preparations by diclofenac. However, larger repolarization prolongation was observed when repolarization reserve was impaired by previous application of BaCl₂. In anaesthetized rabbits, diclofenac did not prolong the QTc interval and did not induce TdP when administered alone. In contrast, when diclofenac was administered after the I_{Kr} blocker dofetilide it further increased the QTc interval and the incidence of TdP. In addition, dofetilide induced TdP in 20% of animals, however, when dofetilide was administered after diclofenac, the incidence of TdP was 62%.

For more than a decade, concerns about increased cardiovascular risks associated with NSAID drugs have been increasing, especially in patients with a history of cardiovascular disease [21,22,23]. The latest network meta-analysis of the cardiovascular safety of NSAID compounds involving more than 116 000 patients clearly suggested that NSAID drug administration was associated with elevated cardiovascular risk, and diclofenac was one of the drugs associated with the highest risk of cardiovascular death [12]. It is not clear from this meta-analysis, however, how the risk of serious ventricular arrhythmia induced sudden cardiac death was influenced by NSAIDs.

The present study focused on the effects of diclofenac on cardiac repolarization, action potential characteristics and on the main transmembrane ionic currents in ventricular muscle, since little is known about the direct cardiac electrophysiological effects and the possible proarrhythmic potency of this drug. Most of the information about the action of diclofenac on ionic currents arises...
from measurements in non-cardiac cells, activating the transient outward K\(^+\) current [24] and inhibiting sodium current [25,26]. It was also observed that diclofenac enhanced KCNQ2/Q3 currents [27], others reported that the drug served as an activator of KCNQ4 and a blocker of KCNQ5 channels [28]. The only ionic current data obtained in ventricular cells were measured by Yarishkin et al. [29], who described inhibition of L-type Ca\(^{2+}\) current by the drug in neonatal rat ventricular myocytes.

Our results showed that diclofenac did not influence \(I_{\text{to}}\) and \(I_{\text{K1}}\) currents even at high concentration but decreased the amplitude of \(I_{\text{Kr}}\) and \(I_{\text{Ks}}\) currents in canine ventricular myocytes. In spite of the significant \(I_{\text{Kr}}\) blockade by the drug just a small but statistically significant action potential lengthening was detected following diclofenac administration in canine ventricular muscle. Some of our other observations may explain these seemingly conflicting results. Diclofenac significantly decreased the maximum upstroke velocity in canine ventricular muscle and also in Purkinje fibers indicating the Na\(^+\) channel blocking property of the drug. It is well established that the late or persistent component of the Na\(^+\) current contributes to the action potential plateau, which is most significant in Purkinje fiber [16]. In Purkinje fiber, diclofenac shortened the action potential duration most probably due to inhibition of the late Na\(^+\) current. Therefore, blockade of this current tends to limit the action potential prolongation resulting from the \(I_{\text{Kr}}\) inhibition by diclofenac. Indeed, a similar reduction of the action potential duration prolonging effect by additional ICa inhibition was demonstrated earlier in the case of the neuroleptic risperidone that blocks \(I_{\text{Kr}}\) [30]. Therefore, the slight decrease of L-type Ca\(^{2+}\) current by high concentration of diclofenac found in this study may also help to counteract the action potential lengthening effect of \(I_{\text{Kr}}\) blockade. The key role of \(I_{\text{Ks}}\) in ventricular repolarization was discussed in earlier works [7,8,31]. Full inhibition of \(I_{\text{Ks}}\) caused only a slight lengthening of repolarization in ventricular preparations, thus in normal canine ventricular muscle \(I_{\text{Ks}}\) plays a minor role in control of APD. This current, however, could provide an important means of limiting excessive APD lengthening when action potential duration is prolonged beyond normal by other mechanisms, thus contributing significantly to repolarization reserve [8]. Therefore, \(I_{\text{Ks}}\) blockade caused by diclofenac might only marginally influence action potential duration but attenuates repolarization reserve.

We characterized \textit{in vitro} and \textit{in vivo} electrophysiological effects of diclofenac: (i) the drug at high concentration inhibits both inward – depolarizing – and outward – repolarizing – transmembrane ionic currents in canine ventricular myocytes, (ii) resulting in only slight repolarization lengthening of ventricular muscle and shortening of the action potential in Purkinje fibers with \textit{normal} repolarization reserve; (iii) diclofenac did not prolong the QTc interval in anaesthetized rabbits. This implies that diclofenac may not augment spatial repolarization heterogeneity. However, in preparations with \textit{impaired} repolarization reserve, much larger lengthening of the action potential duration was observed after application of the drug. Moreover, in our \textit{in vivo} anaesthetized rabbit model when repolarization reserve was

---

**Figure 5. Effect of diclofenac on the rapid \((I_{\text{Kr}})\) and slow \((I_{\text{Ks}})\) component of the delayed rectifier potassium currents in canine ventricular myocytes.** Top panels show representative current traces (A, \(I_{\text{Kr}}\); B, \(I_{\text{Ks}}\)), bottom panels represent current – voltage relationships under control conditions and in the presence of 30 \(\mu\)M diclofenac. Insets indicate the voltage protocol applied during measurements. Data are expressed as mean ± SEM, \(n\) = number of measurements/number of animals.

doi:10.1371/journal.pone.0053255.g005
Impaired, diclofenac further increased QTc interval and the incidence of TdP while administered alone did not induce any TdP.

According to the concept of repolarization reserve [1, 2, 32], normal repolarization is accomplished by multiple potassium channels providing a strong safety reserve for repolarization. Since inhibition or dysfunction of structural origin of one potassium channel does not necessarily lead to clinically manifest prolongation of repolarization, other potassium channels can take over the loss of function. However, a heart with impaired repolarization reserve is more vulnerable to arrhythmia development, since inhibition of another potassium channel by drugs may lead to significant inhomogenous repolarization prolongation and to serious cardiac dysrhythmias [3]. In the present study, the influence of diclofenac on action potential prolongation and to serious cardiac dysrhythmias was also investigated after impairment of the repolarization reserve by adding 30 μM BaCl2, which partially blocks IK1 current. The drug induced a marked action potential lengthening, i.e. the APD lengthening effect of diclofenac was significantly larger in these conditions than in ventricular preparations with normal repolarization reserve.

Repolarization reserve can be reduced by several congenital or acquired pathophysiological conditions [3], as well as reversible cardiac hypertrophy (athlete’s heart). Downregulation or dysfunction of the IKs current plays a critical role in the development of cardiac repolarization reserve impairment [33, 8]. In competitive athletes, slight impairment of repolarization reserve [34] does not result in a significant risk of arrhythmia but together with additional factors (increased sympathetic tone, seemingly harmless medications, doping agents, dietary constituents, hypokalemia, early and undiagnosed cardiomyopathy or other pathological anomalies), these hits on repolarization may add up and can cause repolarization abnormalities occasionally leading to sudden cardiac death [for a recent review see [3]]. In this regard, we found higher beat-to-beat variability of the QTc interval, a novel ECG parameter characterizing temporal instability of cardiac repolarization [35], in professional soccer players compared to their age-matched controls with no significant sports activities [36].

The applied concentration of diclofenac in the present study was somewhat higher than the reported therapeutic blood level, which is approximately 2–7 μM/L based on the data after 50 mg oral administration of diclofenac [37, 38]. Diclofenac strongly binds to plasma albumin [39], complicating the comparison of in vitro and in vivo data. In addition, substantial interpatient variabilities in unbound NSAID plasma concentrations and a poor correlation between concentration and therapeutic response to NSAIDs have been found [39]. It is well known that top athletes widely use NSAIDs, to treat their sports injuries frequently diclofenac, in larger doses [13] that can result in significantly higher plasma and tissue levels. In an in vivo animal study, application of diclofenac in therapeutic doses resulted in higher plasma concentration: a single 50 mg oral dose of diclofenac led to 6 μg/mL (approximately 20 μM/L) peak plasma concentration in Beagle dogs [40]. In clinical settings, diclofenac plasma levels can be increased by dietary constituents (e.g. grapefruit, pineapple juices) and co-administered medications interfering with its metabolism [41, 42, 43, 44, 45] or plasma protein binding [46].

Study Limitations

BaCl2 was used as a tool to impair repolarization reserve in ventricular muscle preparations only, since in Purkinje fibers it was reasonable to expect that BaCl2 would have affected the slope of diastolic depolarization and would have influenced action potential measurements.

The actual plasma levels of diclofenac in anesthetized rabbits were not measured under the present experimental conditions, we relied on firm data from the literature to determine the dose and concentrations of diclofenac used in the experiments.

Conclusions

In the normal heart, diclofenac at therapeutic and even at higher concentrations does not markedly influence ventricular repolarization and arrhythmia risk. However, high-dose treatment with the drug may enhance proarrhythmic risk in situations that lead to reduced repolarization reserve. Therefore, individuals taking diclofenac under proper medical control should not be concerned about proarrhythmic side effects, however, its administration may add to increased risk for serious arrhythmia development in persons associated with subsidiary risk factors including certain diseases or genetic defects that impair repolarization, as well as in individuals taking part in top competitive sports activities. Additional clinical studies are needed to elucidate whether diclofenac increases proarrhythmic risk in patients with congenital and/or acquired diseases and conditions associated with impaired repolarization reserve.

Figure 6. Effect of diclofenac on the L-type calcium current in canine ventricular myocytes. Top panel shows representative current traces, bottom panel represents current – voltage relationships under control conditions and in the presence of 30 μM diclofenac. Inset indicates the voltage protocol applied during measurements. Data are expressed as mean ± SEM, n = number of measurements/number of animals. doi:10.1371/journal.pone.0053255.g006
Author Contributions
Conceived and designed the experiments: JGP AV. Performed the experiments: AK ZK ZH TS IK VJ PB. Analyzed the data: LV IB PB

References
1. Roden DM (1998) Taking the idio out of idiosyncratic-predicting torsades de pointes. Pacing Clin Electrophysiol 21: 1029–1034.
2. Roden DM (2006) Long QT syndrome: reduced repolarization reserve and the genetic link. J Internal Medicine 259: 59–69.
3. Varro A, Baczko I (2011) Cardiac ventricular repolarization reserve: a principle for understanding drug-related proarrhythmic risk. Br J Pharmacol 164: 14–36.
4. Corrado D, Michieli P, Basso C, Schiavon M, Thiene G (2007) How to screen athletes for cardiovascular diseases. Cardiol Clin 25: 391–397.
5. Varro A, Baczko I (2010) Possible mechanisms of sudden cardiac death in top athletes: a basic cardiac electrophysiological point of view. Phaggers Arch 460(1): 31–40.
6. Vos MA, de Groot SH, Verdun SC, van der Zande, J, Leunissen HD, et al. (1998) Enhanced susceptibility for acquired torsade de pointes arrhythmias in the dog with chronic, complete AV block is related to cardiac hypertrophy and electrical remodeling. Circulation 98(11): 1125–1135.
7. Varro A, Balási B, Iost N, Takács J, Virág L, et al. (2000) The role of the delayed rectifier component IKs in dog ventricular muscle and Purkinje fibre repolarization. J Physiol 523(1): 67–81.
8. Jos N, Virág L, Bittay M, Takács J, Lengyel C, et al. (2005) Restricting excessive cardiac action potential and QT prolongation: a vital role for IKs in human ventricular muscle. Circulation 112(10): 1392–1399.
9. Gillon D (2006) Could common painkillers be behind so many players’ deaths? Herald Scotland, Friday 22 September 2006, Accessed 4th January, 2012.
10. McGeorgegan P, Henry D (2006) Cardiovsecular risk and inhibition of cyclo-oxygenase 2: a systematic review of the observational studies of selective and nonselective inhibitors of cyclo-oxygenase 2. JAMA 296(13): 1633–1644.
11. Fosbol EL, Kober L, Torp-Pedersen C, Gislason GH (2010) Cardiovascular safety of non-steroidal anti-inflammatory drugs among healthy individuals. Expert Opin Drug Saf 9(6): 893–903.
12. Trelle S, Riechenbach S, Wandel S, Hildebrandt P, Taka J, et al. (2011) Cardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-analysis. BMJ 342: c7086. doi: 10.1136/bmj.c7086.
13. Duncan JJ, Farr JE (1988) Comparison of diclofenac sodium and aspirin in the treatment of acute sports injuries. Am J Sports Med 16(6): 656–659.
14. Farkas A, Batey AJ, Coker SJ (2002) Proarrhythmic potential of halofantrine, terfenadine and fexofenadine in the rabbit. J Pharmacol Toxicol Methods 47(3): 175–185.
15. Batey AJ, Coker SJ (2002) Proarrhythmic potential of halofantrine, terfenadine and fexofenadine in the rabbit. J Pharmacol Toxicol Methods 47(3): 175–185.
16. Varro A, Baczko I (2011) Cardiac ventricular repolarization reserve: a principle for understanding drug-related proarrhythmic risk. Br J Pharmacol 164(1): 14–36.
17. Vira L, Acsai K, Ha O, Zaza A, Bitay M, et al. (2009) Self-augmentation of cardiac action potential and QT prolongation is attenuated by increased repolarization reserve due to concomitant block of ICa,L. Naunyn Schmiedebergs Arch Pharmacol 371(5): 393–400.
18. Lengyel C, Jos N, Virá L, Varó A, Lathrop DA, et al. (2001) Pharmacological block of the slow component of the outward delayed rectifier current (IKs) fails to lengthen rabbit ventricular muscle QTc and action potential duration. Br J Pharmacol 132(1): 101–110.
19. Roden DM (2006) Repolarization reserve. A moving target. Circulation 114: 981–982.
20. Volders PG, Spitaels KR, Vos MA, Spatjens RL, Leunissen JD, et al. (1999) Downregulation of delayed rectifier K+ currents in dogs with chronic complete atrioventricular block and acquired torsades de pointes. Circulation 100: 2453–2458.
21. Hart G (2003) Exercise-induced cardiac hypertrophy: a substrate for sudden death in athletes? Exp Physiol 88(5): 639–644.
22. Varkevisser R, Wijers SC, Spaetjens RL, Leunissen JD, et al. (1999) Bioavailability of gastric juice-resistant coated diclofenac preparations. 1. Bioavailability study following a single administration of a multiple-unit formulation in comparison with a single-unit formulation. Arzneimittelforschung 49(11): 1211–1215. (In German).
23. Wine’s Drug & Chemical Blood-Level Data 2001
24. Lin JH, Cochetto DM, Duggan DE (1987) Protein binding as a primary determinant of the clinical pharmacokinetics of non-steroidal anti-inflammatory drugs. Clin Pharmacokinet 12(6): 452–452.
25. Al-Jenoobi FI (2010) Effect of itraconazole on the pharmacokinetics of diclofenac in Beagle dogs. Sci Pharm 78: 465–471.
26. Borti R, Macé K, Boobin A, Gómez-Lechón MJ, Pfeifer A, et al. (1999) Hepatic metabolism of diclofenac: role of human CYP in the minor oxidative pathways. Biochem Pharmacol. 58(5): 787–796.
27. Giremavara B, Jayaprakasha GK, Patil BS (2007) Potent inhibition of human cytochrome P450 3A4, 2D6, and 2C9 isoenzymes by grapefruit juice and its fucoxaramins. J Food Sci 72(3): C417–C421.
28. Hidaka M, Nagata M, Kawanoto Y, Sekiya H, Koi H, et al. (2008) Inhibitory effects of fruit juices on cytochrome P450 2C9 activity in vitro. Biosci Biotechnol Biochem 72(2): 406–411.
29. Niemi M, Backman JT, Neuvonen MJ, Laulivaara K, Neuvonen PJ, et al. (2001) Effects of flavonoids and flavonol on the pharmacokinetics and pharmacodynamics of glimepiride. Clin Pharmacol Ther 69(4): 194–200.
30. von Molke LL, Greenblatt DJ, Duan SX, Harmatz JS, Wright CE, et al. (1996) Inhibition of terfenadine metabolism in vitro byazole antifungal agents and by selective serotonin reuptake inhibitor antidepressants: relation to pharmacoki- netic interactions in vivo. J Clin Psychopharmacol 16(2): 104–112.
31. Bird HA, Hill J, Leatham P, Wright V (1986) A study to determine the clinical relevance of the pharmacokinetic interaction between aspirin and diclofenac. Agents Actions 16(3–4): 447–449.

NJ. Wrote the paper: LV IB NJ AV. Drafted and edited the manuscript: LV IB NJ AV JGP.